about
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerSerum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancerBlood peptidome-degradome profile of breast cancerRecommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis.Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.Circulating proteolytic products of carboxypeptidase N for early detection of breast cancerAn open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.HER-2-targeted therapy: lessons learned and future directions.Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.Genome-based risk prediction for early stage breast cancer.HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Breast carcinoma treatment received by women with disabilities compared with women without disabilities.National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.The current status of docetaxel for metastatic breast cancer.Growth factor receptors in breast cancer: potential for therapeutic intervention.Signal transduction inhibitors in the treatment of breast cancer.Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.HER2 therapy: molecular mechanisms of trastuzumab resistance.MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft modelPathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response.Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.Monoclonal antibody-based targeted therapy in breast cancer.Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.Clinical nomogram to predict bone-only metastasis in patients with early breast carcinomaPersonalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
P50
Q27824819-0CA70153-0213-4B73-B2E6-931521934364Q27851582-68F2F577-8F54-4B14-8546-A245E9A9FB35Q28183171-BDB0EB02-BA6D-449D-866D-B1E944D8F346Q28288814-93145C7D-1EBE-47E9-AB98-636B7ACF0802Q28475815-EC317DAD-1C3D-47DB-BDCD-B32A12CBBE2AQ30814798-5A66EEC1-3953-402B-AF3D-5D2A7AA53FAFQ30981573-777C95A3-341A-4B35-AF8A-D0129DC466F4Q31052724-2D676C6F-20D1-4D92-B349-BF4E0EA2B470Q33343161-B0BEFC26-185C-41A1-B673-AD2CB596D541Q33385158-5D2441EF-E630-48F0-8085-4B423171781BQ33389820-D83865FE-2438-4C22-97A2-C35D98F3B014Q33571352-E34CDB7C-0660-4542-85BE-282A499F5ADEQ33685829-E70BE135-15D3-481E-A396-353F31E3D335Q33777427-A141854C-B372-4EB4-9C79-178B6537DD1CQ33840864-C54DB802-6B70-461B-9383-E22523747183Q33947907-09BC7E1C-93DE-4F78-868A-F57F7E83B51FQ33986814-0D79B661-0B90-41F0-85B4-4276C95F4630Q34276302-2FE59B3F-8E37-4AED-BDFC-67CF6CB47364Q34315003-974FA248-11C0-4527-9842-29DA8C2A2EB0Q34359289-EF9E9C16-B0BF-4CD5-ABED-DC9596F96357Q34499609-39249B83-E1F6-420E-B1C4-DFA1612E69B3Q34580447-45F1118C-D767-4D94-AC3B-BE27CF4552E0Q34601116-04E1AD4F-5416-4269-9371-4D428CCD34EBQ34654714-84C7711F-28FF-4337-9BAB-83AEA78D9D80Q34713799-56EAC44A-544E-42D4-9D61-8D732572B12CQ34729174-7BDDD3D3-D3C0-437B-B18B-03B0920A37FEQ35072957-E4F93511-AE6B-4FE4-8504-958B03130343Q35137802-FF777AFD-60B2-438F-AF41-FF3BCC540327Q35170258-6F9170B0-86E5-4D48-A978-DD84D8DDD38FQ35222636-DC9555C4-850C-43C0-8EF6-4FF0A6912C08Q35633712-1A0279FD-186E-4700-926D-9AEADB257810Q35872321-6239528D-36DC-45D4-A398-A063B74C1232Q35873920-8F56D830-A026-49B3-9EAC-4123DCAD8543Q35889261-0BBFFAD4-EF7C-4285-844C-8796DBF4AB73Q36074483-42C07F28-2C00-48EE-ABCE-9954B2586D15Q36208974-8F17B5E0-252E-4E20-9CCE-E21850ADE149Q36295018-A50B1415-AAC6-421A-94CD-DEBA4FBF2598Q36334258-14102915-EAA0-43D4-A064-3C18AD90C5FAQ36365669-34B0D95B-3631-4632-B685-47B9D2B8D728Q36406697-94E96486-5EFD-405E-8D39-8CF49FF556FE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francisco J Esteva
@ast
Francisco J Esteva
@en
Francisco J Esteva
@es
Francisco J Esteva
@nl
Francisco J Esteva
@sl
type
label
Francisco J Esteva
@ast
Francisco J Esteva
@en
Francisco J Esteva
@es
Francisco J Esteva
@nl
Francisco J Esteva
@sl
prefLabel
Francisco J Esteva
@ast
Francisco J Esteva
@en
Francisco J Esteva
@es
Francisco J Esteva
@nl
Francisco J Esteva
@sl
P106
P21
P31
P496
0000-0003-2437-3920